National Institutes of Health

Roughly 83% of the annual budget goes to extramural research via competitive grants to universities, hospitals, and independent labs, per the agency's own budget breakdowns. About 11% funds intramural research conducted by NIH's own scientists on the Bethesda campus. The remainder covers administration, facilities, and oversight.

Annual funding levels are determined by congressional appropriations. The NIH Director and institute leadership set scientific priorities, advised by the Advisory Committee to the Director and institute-level councils predominantly composed of external academic scientists. The White House Office of Management and Budget and the HHS Secretary also shape budget requests before they reach Congress.

NIH itself does not take equity. Under the Bayh-Dole Act, universities and small businesses that receive NIH grants retain title to inventions and may license them, paying a share of royalties to the inventor and institution. NIH can retain a royalty-free license for government use. The FNIH is a separate 501(c)(3) that manages philanthropic donations and public-private partnerships without mingling with appropriated funds.

The NIH Clinical Center in Bethesda is a 200-bed research hospital operating roughly 1,600 clinical research protocols in a typical year. It treats patients enrolled in NIH-led studies — almost exclusively for research, not community care. External researchers can collaborate with NIH intramural investigators to access it, but they cannot independently schedule patients there.

The Foundation for the National Institutes of Health (FNIH) is a Congressionally-authorized 501(c)(3) that raises private philanthropic funds and manages public-private consortia like the Biomarkers Consortium and PACT. It is legally separate, enabling NIH to collaborate with pharmaceutical and biotech firms under structures that appropriated funds cannot easily support. Partnerships like PACT pooled $220 million from 12 pharmaceutical companies alongside NCI funding.

NIH does not co-invest in the venture-capital sense. A biotech startup receiving an SBIR or STTR grant may have concurrent venture backing, but the grant is a non-dilutive award, not an equity investment. The FNIH, by contrast, does structure cost-sharing consortia where corporate partners and NIH each contribute to a pooled research budget.

The National Center for Advancing Translational Sciences (NCATS), one of NIH's 27 institutes, explicitly targets the 'valley of death' between basic research and clinical application. NCATS' drug repurposing program has screened thousands of approved drugs against novel disease targets, though final development and commercialization remain with for-profit partners.